Granted Patent
B2
US 12,403,165 · App. 18/105,374 · Granted Sep 2, 2025
Oncolytic immunotherapy by tumor micro-environment remodeling
Inventors:
Stephen Howard Thorne (Pittsburgh, PA); Mingrui Zhang (Pittsburgh, PA); Daniel J. Byrd (Pittsburgh, PA)
Assignee:
KaliVir Immunotherapeutcs, Inc.
A61K35/768A61P35/00C07K14/55C07K14/5759C07K14/7158C12N15/86C12N2710/24132C12N2710/24143C12N2710/24171
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure relates to modified oncolytic viruses. The modified oncolytic viruses of the disclosure comprise modification in the viral genome encoding exogenous nucleic acids to enhance the oncolytic immunotherapy by remodeling the tumor microenvironment and with enhanced systemic delivery. The disclosure further relates to compositions comprising the modified oncolytic viruses, kits containing the same, and methods of using the oncolytic viruses.
Claims (32)
1. A modified oncolytic virus comprising:
an exogenous nucleic acid encoding a fusion protein comprising a metabolic modulating protein, wherein the exogenous nucleic acid encoding for the fusion protein comprises:
a region encoding for an IL-2 polypeptide, and
a region encoding for a leptin polypeptide;
an exogenous nucleic acid encoding a chemokine receptor, wherein the chemokine receptor is CCR2; and
a genetic modification in a viral genome of the modified oncolytic virus, wherein the modified oncolytic virus provides for enhanced tumor volume reduction upon systemic delivery to a subject compared to systemic administration of an otherwise identical oncolytic virus not comprising the exogenous nucleic acid encoding the fusion protein.
2. The modified oncolytic virus of claim 1 , wherein the exogenous nucleic acid encoding the chemokine receptor comprises a codon optimized variant of a human coding sequence of the chemokine receptor.
3. The modified oncolytic virus of claim 2 , wherein the fusion protein further comprises a cytokine.
4. The modified oncolytic virus of claim 3 , wherein the genetic modification is a mutation or a deletion of an A52R gene.
5. The modified oncolytic virus of claim 4 , wherein the deletion is a complete or a partial deletion.
6. The modified oncolytic virus of claim 5 , wherein the oncolytic virus further comprises a deletion of a thymidine kinase gene.
7. The modified oncolytic virus of claim 6 , wherein the oncolytic virus comprises measles virus, poliovirus, poxvirus, vaccinia virus, adenovirus, adeno-associated virus, herpes simplex virus, vesicular stomatitis virus, reovirus, Newcastle disease virus, Seneca virus, lentivirus, mengovirus, or myxoma virus.
8. The modified oncolytic virus of claim 7 , wherein the oncolytic virus is a poxvirus.
9. The modified oncolytic virus of claim 8 , wherein the poxvirus is a vaccina virus.
10. The modified oncolytic virus of claim 9 , wherein the vaccinia virus is a Western Reserve strain Vaccinia virus, a Copenhagen strain, an IHD strain, a Wyeth strain, a NYCBOH strain, a Tian Tan strain, a Lister strain, an Ankara strain, a USSR strain, an ACAM2000 strain, a Paris strain, a Bern strain, a Temple of Heaven strain, a Dairen strain, an EM-63 strain, an Evans strain, a King strain, a Patwadangar strain, or a Tash Kent strain.
11. The modified oncolytic virus of claim 1 , wherein the exogenous nucleic acid encoding the fusion protein is cloned into a locus of a thymidine kinase gene.
12. The modified oncolytic virus of claim 1 , wherein the exogenous nucleic acid encoding the chemokine receptor is cloned into a locus of an A52R gene.
13. The modified oncolytic virus of claim 12 , further comprising an exogenous nucleic acid encoding a hyaluronidase.
14. The modified oncolytic virus of claim 13 , further comprising a mutation or a deletion of a viral gene selected from the group consisting of: A1, A2, VH1, A33, 17, K7R, B8R, C12L, B15R, B14R, K1L, N1L, M2L, A49R, A46R, E3L, C4, C16, and a functional domain or a fragment or a variant thereof, or any combinations thereof.
15. The modified oncolytic virus of claim 14 , further comprising an exogenous nucleic acid coding for at least one of: HMGB1, PIAS3, LIGHT, fractalkine, ITAC, IL 15, IL15Ralpha, CCL5, a functional domain or a fragment or a variant thereof, or any combinations thereof.
16. The modified oncolytic virus of claim 1 , wherein the region encoding for the IL-2 polypeptide comprises a sequence having at least about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identity to the sequence of SEQ ID NO: 5.
17. The modified oncolytic virus of claim 1 , wherein the exogenous nucleic acid encoding the fusion protein comprises a sequence having at least about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identity to the sequence of SEQ ID NO: 1.
18. The modified oncolytic virus of claim 1 , wherein the exogenous nucleic acid encoding the chemokine receptor comprises a sequence having at least about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100% identity to the sequence of SEQ ID NO: 2 or SEQ ID NO: 3.
19. A pharmaceutical composition comprising the modified oncolytic virus of claim 1 .
20. The pharmaceutical composition of claim 19 , further comprising at least one of: a solubilizing agent, an excipient, or a pharmaceutically acceptable carrier.
21. The pharmaceutical composition of claim 20 , wherein the excipient comprises one or more of a buffering agent, a stabilizer, an antioxidant, a binder, a diluent, a dispersing agent, a rate controlling agent, a lubricant, a glidant, a disintegrant, a plasticizer, a preservative, or any combinations thereof.
22. The pharmaceutical composition of claim 21 , wherein the excipient comprises di-sodium hydrogen phosphate dihydrate, sodium dihydrogen phosphate dihydrate, sodium chloride, myo-inositol, sorbitol, or any combinations thereof.
23. The pharmaceutical composition of claim 22 , further comprising one or more of a preservative, a diluent, and a carrier.
24. The pharmaceutical composition of claim 23 , further comprising an additional active ingredient or a salt thereof.
25. The pharmaceutical composition of claim 24 , wherein the solubilizing agent is sterile water.
26. The modified oncolytic virus of claim 1 , wherein the oncolytic virus is a poxvirus.
27. The modified oncolytic virus of claim 26 , wherein the poxvirus is a vaccina virus.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 3, 2023
From: THORNE, STEPHEN HOWARD; ZHANG, MINGRUI; BYRD, DANIEL J.
To: KALIVIR IMMUNOTHERAPEUTICS, INC.
Reel/Frame 062582/0892 →
Continuity (3)
Continuation
PCTUS2021059887
· Nov 18, 2021
Provisional Application
63116004
· Nov 19, 2020
References Cited (400)
US 4458066A
· Caruthers
· 1984
[cited by applicant]
US 4797368A
· Carter
· 1989
[cited by applicant]
US 5139941A
· Muzyczka
· 1992
[cited by applicant]
US 5530020A
· Gunawardana
· 1996
[cited by applicant]
US 5543158A
· Gref
· 1996
[cited by applicant]
US 5912264A
· Wittman
· 1999
[cited by applicant]
US 6194388B1
· Krieg
· 2001
[cited by applicant]
US 6198323B1
· Offord
· 2001
[cited by applicant]
US 6207646B1
· Krieg
· 2001
[cited by applicant]
US 6352856B1
· Falkner
· 2002
[cited by applicant]
US 6506559B1
· Fire
· 2003
[cited by applicant]
US 6573099B2
· Graham
· 2003
[cited by applicant]
US 6579865B2
· Mak
· 2003
[cited by applicant]
US 6610860B2
· Holton
· 2003
[cited by applicant]
US 6967023B1
· Eini
· 2005
[cited by applicant]
US 6994863B2
· Eini
· 2006
[cited by applicant]
US 7105184B2
· Pauly
· 2006
[cited by applicant]
US 7368122B1
· Dow
· 2008
[cited by applicant]
US 8383774B2
· Hill
· 2013
[cited by applicant]
US 8536380B2
· Scheffler
· 2013
[cited by applicant]
US 8940534B2
· Sandig
· 2015
[cited by applicant]
US 9180091B2
· Bernick
· 2015
[cited by applicant]
US 9289382B2
· Bernick
· 2016
[cited by applicant]
US 20020041864A1
· Fanslow, III
· 2002
[cited by applicant]
US 20020123099A1
· Weiner
· 2002
[cited by applicant]
US 20030180352A1
· Patel
· 2003
[cited by applicant]
US 20040143026A1
· Shah
· 2004
[cited by applicant]
US 20040214783A1
· Terman
· 2004
[cited by applicant]
US 20060057553A1
· Aguilar-Cordova
· 2006
[cited by applicant]
US 20060099188A1
· Tagawa
· 2006
[cited by applicant]
US 20060099224A1
· Kirn
· 2006
[cited by applicant]
US 20060111278A1
· Thim
· 2006
[cited by applicant]
US 20070029054A1
· Nien
· 2007
[cited by applicant]
US 20100016224A1
· Bowie
· 2010
[cited by applicant]
US 20100094560A1
· Lois
· 2010
[cited by applicant]
US 20110274711A1
· Favier
· 2011
[cited by examiner]
US 20150105276A1
· Hofmann
· 2015
[cited by applicant]
US 20160060311A1
· Jo
· 2016
[cited by applicant]
US 20170016028A1
· Yla-Herttuala
· 2017
[cited by applicant]
US 20180000733A1
· Chakroborty
· 2018
[cited by applicant]
US 20200009203A1
· Sobol
· 2020
[cited by applicant]
US 20200054677A1
· Mccoll
· 2020
[cited by applicant]
US 20200268831A1
· Tobin
· 2020
[cited by applicant]
US 20220033784A1
· Binder
· 2022
[cited by applicant]
US 20230002740A1
· Kirn
· 2023
[cited by applicant]
US 20230201283A1
· Binder
· 2023
[cited by applicant]
US 20230405105A1
· Bendjama
· 2023
[cited by applicant]
CN 101381742A
· 2009
[cited by applicant]
CN 1754002B
· 2010
[cited by applicant]
CN 111556757A
· 2020
[cited by applicant]
CN 108350434B
· 2022
[cited by applicant]
EP 0119621A1
· 1984
[cited by examiner]
EP 185573A
· 1986
[cited by applicant]
EP 488528A
· 1992
[cited by applicant]
EP 0689454B1
· 1994
[cited by applicant]
EP 2212696B1
· 2013
[cited by applicant]
JP 6012986A
· 1985
[cited by applicant]
JP 2007244382A
· 2007
[cited by applicant]
KR 20140122603A
· 2014
[cited by applicant]
WO 9118088A1
· 1991
[cited by applicant]
WO 199309239A1
· 1993
[cited by applicant]
WO 199412649A1
· 1994
[cited by applicant]
WO 199426914A1
· 1994
[cited by applicant]
WO 199428152A1
· 1994
[cited by applicant]
WO 199428938A1
· 1994
[cited by applicant]
WO 199502697A1
· 1995
[cited by applicant]
WO 199622378A1
· 1996
[cited by applicant]
WO 1999032619A1
· 1999
[cited by applicant]
WO 0102703A1
· 2001
[cited by applicant]
WO 2001036646A1
· 2001
[cited by applicant]
WO 2001068836A1
· 2001
[cited by applicant]
WO 2003035683A2
· 2003
[cited by applicant]
WO 2004018478A2
· 2004
[cited by applicant]
WO 2008023077A2
· 2008
[cited by applicant]
WO 2008100292A2
· 2008
[cited by applicant]
WO WO2008142479A2
· 2008
[cited by examiner]
WO 2012089225A1
· 2012
[cited by applicant]
WO 2013038066A1
· 2013
[cited by applicant]
WO 2014048500A1
· 2014
[cited by applicant]
WO 2015027163A1
· 2015
[cited by applicant]
WO 2015103438A2
· 2015
[cited by applicant]
WO 2016033555A1
· 2016
[cited by applicant]
WO 2016061286A1
· 2016
[cited by applicant]
WO 2016144564A2
· 2016
[cited by applicant]
WO 2017013419A1
· 2017
[cited by applicant]
WO 2017043815A1
· 2017
[cited by applicant]
WO 2017112741A1
· 2017
[cited by applicant]
WO 2017165464A1
· 2017
[cited by applicant]
WO 2018057755A1
· 2018
[cited by applicant]
WO 2018058258A1
· 2018
[cited by applicant]
WO 2018091680A1
· 2018
[cited by applicant]
WO 2019089755A1
· 2019
[cited by applicant]
WO 2019148109A1
· 2019
[cited by applicant]
WO 2019213452A1
· 2019
[cited by applicant]
WO 2020033791A1
· 2020
[cited by applicant]
Genbank Accession No. NM_001123041.3 Human CCR2 mRNA. Earliest priority 1988. 5 pages.
[cited by examiner]
Genbank Accession No. NM_000586.4,
[cited by examiner]
Yu et al., Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol, vol. 22, p. 313-20 (2004).
[cited by applicant]
Yue et al., Targeting STAT3 in cancer: how successful are we? Expert Opin. Investig. Drugs, vol. 18(1), p. 45-56 (2009).
[cited by applicant]
Zamarin et al., Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity, Nature Communication, 2017; 8: p. 1-14.
[cited by applicant]
Zeh H, et al., First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread and Anti-tumor Activity. Molecular Therapy, vol. 23, No. 1, Jan. 2015.
[cited by applicant]
Zhang et al., Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res, vol. 67, p. 10038-46 (2007).
[cited by applicant]
Zhu et al., High-throughput screening for TLR3-IFN regulatory factor 3 signaling pathway modulators identifies several antipsychotic drugs as TLR inhibitors. Journal of Immunology, vol. 184, p. 5768-76 (2010).
[cited by applicant]
Zhu et al., Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-B. Blood, vol. 109, p. 619-25 (2007).
[cited by applicant]
Zufferey et al., Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery, J. Virol., 1998, vol. 72, p. 9873-80.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2018/058456, mailed Feb. 5, 2019.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2020/012611, mailed Apr. 20, 2020.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2020/056107, mailed Mar. 1, 2021.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2020/056130, mailed Feb. 8, 2021.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2021/059887, mailed Feb. 2, 2022.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2022/026703, mailed Oct. 5, 2022.
[cited by applicant]
International Search Report and Written Opinion for PCT/US2022/033524, mailed Nov. 23, 2022.
[cited by applicant]
International Search Report for PCT/US2017/042910, mailed Mar. 6, 2018.
[cited by applicant]
International Search Report for PCT/US2017/052746, mailed Feb. 13, 2018.
[cited by applicant]
International Search Report for PCT/US2019/015434, mailed Apr. 5, 2019.
[cited by applicant]
International Search Report for PCT/US2019/062643, mailed Mar. 31, 2020.
[cited by applicant]
Pearson et al., Improved Tools for Biological Sequence Comparison, Proc. Natl. Acad. Sci. USA vol. 85, p. 2444-2448, 1988.
[cited by applicant]
Penna, et al., Cutting Edge: Differential Chemokine Production by Myeloid and Plasmacytoid Dendritic Cells, J. Immunol., vol. 69, p. 6673-6676, (2002).
[cited by applicant]
Peritt, et al., Cutting Edge: Differentiation of Human NK Cells into NK1 and NK2 Subsets, J. Immunol., vol. 161, p. 5821-5824 (1998).
[cited by applicant]
Perry et al., Clinical Scale Expansion of Human Pluripotent Stem Cells, Blood, vol. 106(11), (2005), Abstract Only.
[cited by applicant]
Persing et al., Taking Toll: Lipid A Mimetics as Adjuvants and Immunomodulators, Trends in Microbiology, vol. 10, No. 10, S32-S37, 2002.
[cited by applicant]
Pharmaceutical Preformulation and Formulation, CRC Press LLC: Boca Raton, FL, 2004).
[cited by applicant]
Pipiya et al., Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression, Gene Ther 2005, vol. 12(11). pp. 911-917.
[cited by applicant]
Pol et al., Preclinical Evaluation of an Oncolytic Mamba Virus Vaccine in a Simian Model. 7th International Oncolytic Viruses Meeting (Quebec City, 2013).
[cited by applicant]
Prestwich et al., Immune-mediated Antitumor Activity of Reovirus is Required for Therapy and is Independent of Direct Viral Oncolysis and Replication. Clin Cancer Res, vol. 15, o4374-81 (2009).
[cited by applicant]
Prestwich et al., Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 14(22), p. 7358-66 (2008).
[cited by applicant]
Puhlmann et al., Vaccinia is a vector for tumor-directed gene therapy: Biodistribution of a thymidine kinase-deleted mutant, Cancer Gene Ther, vol. 7, p. 676-73, 2000.
[cited by applicant]
Pulido et al., Using Virally Expressed Melanoma cDNA Libraries to Identify Tumor-associated Antigens that Cure Melanoma. Nature Biotechnology, vol. 30, p. 337-43 (2012).
[cited by applicant]
Putz et al., Quantification of Antibody Responses Against Multiple Antigens of the Two Infectious Forms of Vaccinia Virus Provides a Benchmark for Smallpox Vaccination. Nat Med, vol. 12, p. 1310-5 (2006).
[cited by applicant]
Rakoff-Nahoum et al. Toll-like Receptors and Cancer. Nature Reviews. Cancer, vol. 9, p. 57-63 (2009).
[cited by applicant]
Reading et al., Vaccinia Virus Interleukin-18-Binding Protein Promotes Virulence by Reducing Gamma Interferon Production and Natural Killer and T-cell Activity. J Virol, vol. 77, p. 9960-8 (2003).
[cited by applicant]
Rehm et al., Vaccinia Virus A35R Inhibit MHC Class II Antigen Presentation, Virology, vol. 397(1), p. 176-86, 2010.
[cited by applicant]
Ricca et al., Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy, Mol Ther 2018, vol. 26(4), pp. 1008-1019.
[cited by applicant]
Rivadeneira, et al. Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance. Immunity, vol. 51, p. 548-560. 2019.
[cited by applicant]
Robins et al., Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells, Blood 2009, vol. 114(19), p. 4099-107.
[cited by applicant]
Rojas J, Sampath P, Hou W, Thorne SH, Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. Clin. Cancer Res., (2015), PMID: 26187615.
[cited by applicant]
Roman et al., Central Leptin Action Improves Skeletal Muscle AKT, AMPK, and PGC1a Activation by Hypothalamic PI3k-Dependent Mechanism, Mol Cell Endocrinol, vol. 314(1), p. 62-9, 2010.
[cited by applicant]
Rommelfanger et al., Systemic Combination Virotherapy for Melanoma with Tumor Antigen-Expressing Vesicular Stomatitis Virus and Adoptive T-Cell Transfer. Cancer Research, p. 2753-4764 (2012).
[cited by applicant]
Roper et al., Characterization of the Vaccinia Vrius A35R Protein and its Role in Virulence, J of Virology, vol. 80, No. 1, p. 306-313, 2006.
[cited by applicant]
Rosenberg et al., Cancer Immunotherapy: Moving Beyond Current Vaccines. Nat Med, vol. 10, p. 909-15 (2004).
[cited by applicant]
Russell et al., Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines, Cancer Cell 2018, vol. 33(4), pp. 599-605.
[cited by applicant]
Saikh, et al., Toll-Like Receptor and Cytokine Expression Patterns of CD56+ T Cells Are Similar to Natural Killer Cells in Response to Infection with Venezuelan Equine Encephalitis Virus Replicons, J. Infect. Dis., vol.…
[cited by applicant]
Sakamoto, et al., Characteristics of T-cell Receptor Va24JaQ T Cells, a Human Counterpart of Murine NK1+ T Cells, from Normal Subjects, J. Allergy Clin. Immunol., vol. 103, S445-S451, 1999.
[cited by applicant]
Sambrook et al. (ed.), Molecular Cloning: A Laboratory Manual 2nd ed., vol. 1-3, Cold Spring Harbor Laboratory Press, Cold Spring, Harbor, N.Y., 1989.
[cited by applicant]
Sampath et al., Crosstalk Between Immune Cell and Oncolytic Vaccinia Therapy Enhances Tumor Trafficking and Antitumor Effects, Molecular Ther., vol. 21, No. 3, p. 620-628, 2013.
[cited by applicant]
Sampath P, et al., Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses. Oncolytic Virotherapy, vol. 3, p. 1-9, 2013.
[cited by applicant]
Sampath P, et al., Novel therapeutic strategies in human malignancy: Combining immunotherapy and oncolytic virotherapy. Oncolytic Virotherapy, vol. 4, p. 75-82, (2015).
[cited by applicant]
Samuelsson et al., Survival of Lethal Poxvirus Infection in Mice Depends on TLR9, and Therapeutic Vaccination Provides Protection. J Clin Invest, vol. 118, p. 1776-84 (2008).
[cited by applicant]
Santos-Alvarez et al., Human Leptin Stimulates Proliferation and Activation of Human Circulating Monocytes, Cell Immunol, vol. 194, p. 6-11, 1999.
[cited by applicant]
Sasaki et al., Regulation of DNA-raised Immune Responses by Cotransfected Interferon Regulatory Factors. Journal of Virology, vol. 76, 6652-9 (2002).
[cited by applicant]
Satija et al., Spatial reconstruction of single-cell gene expression, Nat Biotechnol 2015, vol. 33(5), pp. 495-502.
[cited by applicant]
Sato et al., Toll/IL-1 Receptor Domain-Containing Adaptor Inducing IFN-B (TRIF) Associates . . . in the Toll-Like Receptor Signaling1, Journal of Immunology, vol. 171, p. 4304-10 (2003).
[cited by applicant]
Sautes-Fridman et al., Tumor Microenvironment is Multifaceted. Cancer Metastasis Reviews, vol. 30, vol. 13-25, 2011.
[cited by applicant]
Schafer et al., Vaccinia virus-mediated intra-tumoral expression of matrix metalloproteinase 9 enhances oncolysis of PC-3 xenograft tumors, BMC Cancer, 2012, vol. 12, No. 366, p. 1-9.
[cited by applicant]
Scharping et al., Efficacy of PD-1 Blockade is Potentiated by Metformin-induced Reduction of Tumor Hypoxia, Cancer Immunol. Res., vol. 5, p. 9-16, 2017.
[cited by applicant]
Scharping et al., The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and DysfunctionImmunity 2016; vol. 45(3), p. 374-388, 2016.
[cited by applicant]
Schmidt, Amgen Spikes Interest in Live Virus Vaccines for Hard-to-Treat Cancers. Nature Biotechnology, vol. 29, p. 295-6 (2011).
[cited by applicant]
Senzer et al., Phase II Clinical Trial of a Granulocyte-Macrophage Colony-stimulating Factor-encoding, Second-generation Oncolytic Herpesvirus in Patients with Unresectable Metastatic Melanoma. J Clin Oncol, vol. 27, p.…
[cited by applicant]
Setoguchi et al., Homeostatic Maintenance of Natural Foxp3(+) CD25(+) CD4(+) Regulatory T Cells by Interleukin (IL)-2 and Induction of Autoimmune Disease by IL-2 Neutralization. The Journal of Experimental Medicine, vol…
[cited by applicant]
Shao L et al., (2019) IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell. Cancer Immunol Res., vol. 7, Issue 8:1258-1266.
[cited by applicant]
Sharma et al, The PTEN Pathway in Tregs is a Critical Driver of the Suppressive Tumor Microenvironment, Sci. Advance, p. 1-15, 2015.
[cited by applicant]
Sharma et al., Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy, Cell, vol. 168(4), p. 707-23, 2017.
[cited by applicant]
Sibelius et al., Role of Listeria Monocytogenes Exotoxins Listeriolysin and Phosphatidylinositol-Specific Phospholipase C in Activation of Human Neutrophils, Infection Immunity, vol. 67, p. 1125-1130, 1999.
[cited by applicant]
Sidobre, et al., The T Cell Antigen Receptor Expressed by Va14i NKT Cells has a Unique Mode of Glycosphingolipid Antigen Recognition, Proc. Natl. Acad. Sci., vol. 101, p. 12254-12259, 2004.
[cited by applicant]
Silva et al., Aldehyde Dehydrogenase in Combination with CD 133 Defines Angiogenic Ovarian Cancer Stem Cells that Portend Poor Patient Survival. Cancer Research, vol. 71, p. 3991-4001 (2011).
[cited by applicant]
Siveen et al., Targeting the STAT3 Signaling Pathway in Cancer: Role of Synthetic and Natural Inhibitors, Biochimica et Biophysica Acta, vol. 1845, p. 136-154 (2014).
[cited by applicant]
Kobayashi, et al., Bacterial Pathogens Modulate an Apoptosis Differentiation Program in Human Neutrophils, Proc. Natl. Acad. Sci. USA, vol. 100, p. 10948-10953, 2003.
[cited by applicant]
Kochneva et al., Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy, Oncotarget, 2016, vol. 7, No. 45, p. 74171-74188.
[cited by applicant]
Kolb-Maurer et al., Listeria Monocytogenes-Infected Human Dendritic Cells: Uptake and Host Cell Response, Infection Immunity, vol. 68, p. 3680-3688, 2000.
[cited by applicant]
Kowalsky et al., Superagonist IL-15Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy that are Enchanced with PD-1 Blockadge, Molecular Therapy, Nature Publishing Group, 2018, vol. 26, No. 10, p. 2476-2…
[cited by applicant]
La Cava et al., The Weight of Leptin in Immunity, Nat Rev Immunol, vol. 4, p. 371-379, 2004.
[cited by applicant]
La-Beck et al., Erratum, 2015 Pharmacotherapy Publications, Inc.
[cited by applicant]
Lalvani et al., Rapid Effector Function in CD8+ Memory T Cells, J. Exp. Med., vol. 186, p. 859-865, 1997.
[cited by applicant]
Langland et al., The Role of the PKR-Inhibitory Genes, E3L and K3L, in Determining Vaccinia Virus Host Range, Virology. vol. 299(1), p. 133-41, 2002.
[cited by applicant]
Lawler et al. Oncolytic Viruses in Cancer Treatment, JAMA Oncology, Jun. 1, 2017, vol. 3, No. 6, pp. 841-849.
[cited by applicant]
Le et al., CDS(+) Foxp3(+) Tumor Infiltrating Lymphocytes Accumulate in the Context of an Effective Anti-tumor Response. International Journal of Cancer. Journal International du Cancer, vol. 129, p. 636-47 (2011).
[cited by applicant]
Lemoine et al., Massive Expansion of Regulatory T-cells Following Interleukin 2 Treatment During a Phase 1-11 Dendritic Cell-based Immunotherapy of Metastatic Renal Cancer. International Journal of Oncology, vol. 35, No…
[cited by applicant]
Levero et al., Defective and Nondefective Adenovirus Vectors for Expressing Foreign Genes in Vitro and in Vivo, Gene, 1991, vol. 101, p. 195-202, 1991.
[cited by applicant]
Li et al., CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency. J Immunother Cancer. 8(1):e000131, 2020, PMID: 32098828.
[cited by applicant]
Li J, et al., (2011) Chemokine Expression From Oncolytic Vaccinia Virus Enhances Vaccine Therapies of Cancer. Molecular Therapy, vol. 19, No. 5, pp. 650-657, 2011.
[cited by applicant]
Liu et al., The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, Antivascular, and Anti-HBV Activities in Patients with Hepatocellular Carcinoma. Mol Ther, vol. 16, p. 1637-42 (2008).
[cited by applicant]
Loffreda et al., Leptin Regulates Proinflammatory Immune Responses, FASEB J, vol. 12, 57-65, 1998.
[cited by applicant]
Longhi, M.P., et al., Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Thl immunity with poly IC as adjuvant. The Journal of Experimental Medicine, vol. 206, p. 1589-1602 (2009).
[cited by applicant]
Lun et al., “Effects of Intravenously Administered Recombinant Vesicular Stomatitis Virus (VSV-delta-M51) on Multifocal and Invasive Gliomas”, Journal of the National Cancer Institute, 2006, vol. 98, No. 21, p. 1546-155…
[cited by applicant]
Mahoney et al., Combination cancer immunotherapy and new immunomodulatory targets, Cancer Immunotherapy, Nature Reviews, Drug Discovery, vol. 14, Aug. 2015, pp. 561-584.
[cited by applicant]
Mailliard et al., Alpha-type-I Polarized Dendritic Cells: A Novel Immunization Tool with Optimized CTL-inducing Activity. Cancer Res, vol. 64, p. 5934-7, (2004).
[cited by applicant]
Martin-Romero et al., Human Leptin Enhances Activation and Proliferation of Human Circulating T Lymphocytes, Cell Immunol, vol. 199(1), p. 15-24, 2000.
[cited by applicant]
Mccart et al., Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res, vol. 61, p. 8751-7 (2001).
[cited by applicant]
Mcheyzer-Williams et al., Enumeration and Characterization of Memory Cells in the Th Compartment, Immunol. Rev., vol. 150, p. 5-21, 1996.
[cited by applicant]
Mcintosh et al., Vaccinia Virus Glycoprotein A34R is Required for Infectivity of Extracellular Enveloped Virus. J Virol, vol. 70:, p. 272-81, 1996.
[cited by applicant]
Mcmanus et al., Gene Silencing Using Micro-RNA Designed Hairpins, RNA, vol. 8, p. 842-850, (2002).
[cited by applicant]
Mcmichael et al., A New Look at T Cells, J. Exp. Med., vol. 187(9), p. 1367-1371, 1998.
[cited by applicant]
Meyer et al., Mapping of Deletions in the Genome of the Highly Attenuated Vaccinia Virus MVA and Their Influence on Virulence, J. of General Virology, vol. 72, p. 1031-1038, 1991.
[cited by applicant]
Millipore Sigma, Benzonase endonuclease, SAFC, 2018, pp. 1-40.
[cited by applicant]
Moleirinho et al., Clinical-grade Oncolytic Adenovirus Purification Using Polysorbate 20 as an Alternative for Cell Lysis, Current Gene Therapy, 2018, vol. 18, p. 366-374.
[cited by applicant]
Moon EK et al., Intra-tumoral delivery of CXCL 11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines. Oncoimmunology, vol. 7, Issue 3, 2018.
[cited by applicant]
Moss B. Poxviridae: The Viruses and Their Replication. Field's Virology (eds. D.M., K., Fields, B.N. & Howley, P.M.) Ch.84 (Lippincott-Raven, Philadelphia, 2001).
[cited by applicant]
Myers and Miller, Approximate matching of regular expressions, Bulletin of Mathematical Biology, vol. 51, Issue 1, p. 5-37; (1989).
[cited by applicant]
Paul et al., Tumor Gene Therapy by MVA-Mediated Expression of T-Cell-Stimulating Antibodies, Cancer Gene Ther., vol. 9, p. 470-7, 2002.
[cited by applicant]
Najjar et al., Clinical Perspectives on Targeting of Myeloid Derived Suppressor Cells in the Treatment of Cancer, Frontiers in Oncology, vol. 3(49), p. 1-9, 2013.
[cited by applicant]
Naldini, Nuclear Acid Delivery: Lentiviral and Retroviral Vectors, Curr. Opin. Biotechnol., vol. 9, p. 457-63, 1998.
[cited by applicant]
Narang et al., Improved Phosphotriester Method for Synthesis of Gene Fragments, Meth. Enzymol., vol. 68, p. 90-99, 1979.
[cited by applicant]
Needham-Vandevanter et al., Characterization of an Adduct between CC-1065 and a Defined Oligodeoxynucleotide Duplex, Nucl. Acids Res., vol. 12, p. 6159-6168, 1984.
[cited by applicant]
Needleman et al., A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins,, J. Mol. Biol., vol. 48, p. 443-453, 1970.
[cited by applicant]
Nestle et al., Cancer Vaccines: The Next Generation of Tools to Monitor the Anticancer Immune Response. PLoS Med 2, e339 (2005).
[cited by applicant]
Ning et al., Cancer Stem Cell Vaccination Confers Significant Antitumor Immunity. Cancer Research, vol. 72, p. 1853-64 (2012).
[cited by applicant]
Nishio et al., Oncolytic Virus Expressing RANTES and IL-15 Enhances Function of CAR-Modified T Cells in Solid Tumors, Oncoimmunology, Mar. 6, 2015 (Mar. 6, 2015), vol. 4, No. 2, pp. 1-3.
[cited by applicant]
O'Gorman et al., Alternate Mechanisms of Initial Pattern Recognition Drive Differential Immune Responses to Related Poxviruses. Cell Host & Microbe, vol. 8, p. 174-85 (2010).
[cited by applicant]
Okada et al., Induction of CD8+ T-cell Responses Against Novel Glioma-associated Antigen Peptides and . . . Carboxymethylcellulose in Patients with Recurrent Malignant Glioma. Journal of Clinical Oncology : Official Jou…
[cited by applicant]
Okamura, H., et al. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature, vol. 378, p. 88-91 (1995).
[cited by applicant]
O'Neill et al., Therapeutic Targeting of Toll-like Receptors for Infectious and Inflammatory Diseases and Cancer. Pharmacological Reviews, vol. 61, p. 177-97 (2009).
[cited by applicant]
Orubu et al., Expression and Cellular Immunogenicity of a Transgenic Antigen Driven by Endogenous Poxviral Early Promoters at Their Authentic Loci in MVA, PLOS One 7:e40167, 2012.
[cited by applicant]
Ottolino-Perry et al. Intelligent Design: Combination Therapy With Oncolytic Viruses, Molecular Therapy, Feb. 28, 2010, vol. 18, No. 2, pp. 251-263.
[cited by applicant]
Parato et al., The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers, Molecular Therapy, vol. 20, No. 4, p. 749-758, 2012.
[cited by applicant]
Park et al., Use of a Targeted Oncolytic Poxvirus, JX-594, in Patients with Refractory Primary or Metastatic Liver Cancer: A Phase I Trial. Lancet Oncol, vol. 9, p. 533-42 (2008).
[cited by applicant]
Benfield et al., Vaccinia virus protein K7 is a virulence factor that alters the acute immune response to infection; Journal of General Virology, 2013, vol. 94, p. 1647-1657.
[cited by applicant]
Di Pilato et al., NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses, PNAS, 2015, p. E1333-E1342.
[cited by applicant]
Furusato et al., CXCR4 and Cancer, AM Fulton, Chemokine Receptors in Cancer, Cancer Drug Discovery and Development, 2009, p. 31-45.
[cited by applicant]
KaliVir Poster Presentation 894; A novel oncolytic immunotherapy, VET3-TGI, overcomes TGFB1 mediated immunosuppression, augments type-1 immune response, and displays potent therapeutic activity in multiple mouse tumor m…
[cited by applicant]
Kleinpeter et al., Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allows their intratumorial delivery and an improved tumor-growth inhibition, Oncoim…
[cited by applicant]
Lim et al., Targeting the CCL2-CCR2 signaling axis in cancer metastasis, Oncotarget, 2016, vol. 7, No. 19, p. 28697-28710.
[cited by applicant]
Lin et al., Direct Priming of CD8+ T Cells Persists in the Face of Cowpox Virus Inhibitors of Antigen Presentation, Journal of Virology, 2021, vol. 95, Issue 10, e00186_21, p. 1-15.
[cited by applicant]
Muthuswamy et al., A novel oncolytic immunotherapy, VET3-TGI, overcomes TGFB1 mediated immunosuppression, augments type-1 immune response, and displays potent therapeutic activity in multiple mouse tumor models, Journal…
[cited by applicant]
Ogata et al., Overexpression of PIAS3 Suppresses Cell Growth and Restores the Drug Sensitivity of Human Lung Cancer Cells in Association with PI3-K/Akt Inactivation, Neoplasia, 2006, vol. 8, No. 10, p. 817-825.
[cited by applicant]
Oghumu et al., Transgenic Expression of CXCR3 on T Cells Enhances Susceptibility to Cutaneous Leishmania major Infection by Inhibiting Monocyte Maturation and Promoting Th2 Response, Infection and Immunity, 2015, vol. 8…
[cited by applicant]
Pozzobon et al., CXCR4 signaling in health and disease, Immunology Letters, 2015, vol. 177, p. 6-15.
[cited by applicant]
Raemdonck et al., CXCR3 ligands in disease and therapy, Cytokine & Growth Factor Reviews, 2015, vol. 26, p. 311-327.
[cited by applicant]
Wang et al., An optimized HMGB1 expressed by recombinant rabies virus enhances immunogenicity through activation of dendritic cells in mice, Oncotarget, 2017, vol. 8, No. 48, p. 83539-83554.
[cited by applicant]
Wu et al., Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion, Molecular Cancer, 2012, vol. 11, No. 3, p. 1-16.
[cited by applicant]
Wu et al., Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists, Science, 2010, vol. 330, p. 1066-1071.
[cited by applicant]
Yoshie, Chemokine receptors as therapeutic targets, Japanese Journal of Clinical Immunology, 2013, vol. 36, No. 4, pp. 189-196.
[cited by applicant]
Godin-Ethier, et al., Indoleamine 2,3-dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol. 1…
[cited by applicant]
Goldufsky et al., Oncolytic virus therapy for cancer. Oncolytic Virotherapy, 2013, vol. 2, p. 31-46.
[cited by applicant]
Graham et al., Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5, J. Gen. Virol., vol. 36, p. 59-72, 1977.
[cited by applicant]
Graham, Covalently Closed Circles of Human Adenovirus DNA are Infectious, EMBO J., vol. 3, p. 2917, 1984.
[cited by applicant]
Green, D.R. et al., Immunogenic and Tolerogenic Cell Death. Nature Reviews, Immunology, vol. 9, p. 353-63 (2009).
[cited by applicant]
Guedan et al., Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth, Molecular Therapy, 2010, vol. 18(7), p. 1275-83.
[cited by applicant]
Gulley, et al., Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-based Vaccines in Patients with Metastatic Carcinoma. Clin Cancer Res, vol. 14, p. 3060-9 (2008).
[cited by applicant]
Guo et al., Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives, Front. Oncol., vol. 8, p. 1-15, 2017.
[cited by applicant]
Guo et al., Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity, Frontiers in Oncology, Apr. 10, 2014 (Apr. 10, 2014), vol. 4, No. 74, pp. 1-11.
[cited by applicant]
Guo et al., Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus, Molecular Therapy, Methods and Clinical Development, 2017, vol. 7, p. 112-…
[cited by applicant]
Guo, et al., Oncolytic Virotherapy: Molecular Targets in Tumor-Selective Replication and Carrier Cell-mediated Delivery of Oncolytic Viruses. Biochim Biophys Acta (2008).
[cited by applicant]
Guo, et al., The Enhanced Tumor Selectivity of an Oncolytic Vaccinia Lacking the Host Range and Antiapoptosis Genes SPI-1 and SPI-2. Cancer Res, vol. 65, p. 9991-8 (2005).
[cited by applicant]
Guy, et al., Expression of the Neu Protooncogene in the Mammary Epithelium of Transgenic Mice Induces Metastatic Disease. Proceedings of the National Academy of Sciences of the United States of America, vol. 89, p. 1057…
[cited by applicant]
Hannon, G J., A Conserved Biological Response to Double-stranted RNA, RNA Interference, Nature, vol. 418, p. 244-251, 2002.
[cited by applicant]
Hart et al., Genotypic and phenotypic assessment of hyaluronidase among type strains of a select group of staphylococcal species, International Journal of Microbiology, 2009, vol. 2009, Article 614371, p. 1-8.
[cited by applicant]
Hennessy, et al, Targeting Toll-like Receptors: Emerging Therapeutics? Nature Reviews. Drug Discovery, vol. 9, p. 293-307 (2010).
[cited by applicant]
Herbst et al., Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients, Nature, vol. 515(7528), p. 563-567, 2014.
[cited by applicant]
Higgins, et al., CLUSTAL: a package for performing multiple sequence alignment ona microcomputer, Gene, vol. 73, p. 237-244, 1988.
[cited by applicant]
Higgins, et al., Fast and Sensitive Multiple Sequence Alignments on a Microcomputer, Cabios, vol. 5, No. , p. 151-153, 1989.
[cited by applicant]
Hiley et al., Lister strain vaccinia virus, a potential therapeutic vector targeting hypoxic tumours, Gene Therapy, 2010, vol. 17(2), p. 281-287.
[cited by applicant]
Hokey et al., Tumor Cell Loaded Type-I Polarized Dendritic Cells Induce Thl-mediated Tumor Immunity. Cancer Research, vol. 65, p. 10059-67 (2005).
[cited by applicant]
Hornemann et al., Replication of Modified Vaccinia Virus Ankara . . . Inteferon Resistance Gene E3L, Journal of Virology, vol. 77, No. 15, p. 394-8407, 2003.
[cited by applicant]
Hou W, et al. (2014) Oncolytic Vaccinia Virus Demonstrates Anti-angiogenic Effects Mediated by Targeting of VEGF. Int J Cancer. 2014, vol. 135, p. 1238-1246.
[cited by applicant]
Hsu et al., Leptin-Induced Mitochondrial Fusioni Mediates Hepatic Lipid Accumulation, Int J Obes (Lond) 2015, vol. 39(12), p. 1750-6.
[cited by applicant]
Huang B, et al., Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. Gene Therapy, vol. 18, p. 164-172, 2010.
[cited by applicant]
Hughes et al., A rapid Orthopoxvirus purification protocol suitable for high-containment laboratories, Journal of Virological Methods, 2017, vol. 243, p. 68-73.
[cited by applicant]
Hynes, et al., Analysis of a Second Bacteriophage Hyaluronidase Gene from
[cited by applicant]
Iwasaki, et al., Enhanced CTL Responses Mediated by Plasmid DNA Immunogens Encoding Costimulatory Molecules and Cytokines. Journal of Immunology, vol. 158, p. 4591-601, 1997.
[cited by applicant]
Janssens and Beyaert, Role of Toll-Like Receptors in Pathgen Recognition, Clinical Microb. Revs., vol. 16, p. 637-646, 2003.
[cited by applicant]
Jhawar et al., Oncolytic Viruses—Natural Genetically Engineered Cancer Immunotherapies, Front. Oncol., vol. 7, p. 1-11, 2017.
[cited by applicant]
Jiang et al., Toll-like Receptor 3-Mediated Activation of NF-kappaB and IRF3 Diverges at Toll-IL-I Receptor Domain-Containing Adapter Inducing IFN-beta. Proceedings of the National Academy of Sciences of the United Stat…
[cited by applicant]
Jinushi, et al., MFG-ES-mediated Uptake of Apoptotic Cells by APCs Links the Pro-and-anti-inflammatory activities of GM-CSF. The Journal of Clinical Investigation, vol. 117, p. 1902-13 (2007).
[cited by applicant]
Jones et al., Therapeutic Strategies for the Clinical Blockade of IL-6/gpl30 Signaling. The Journal of Clinical Investigation, vol. 121, p. 3375-83 (2011).
[cited by applicant]
Kafri et al., A Packaging Cell Line for Lentivirus Vectors, J. Virol., vol. 73, No. 1, p. 576-584, 1999.
[cited by applicant]
Kalinski et al., Regulation of Immune Responses by Prostaglandin E2. Journal of Immunology, vol. 188, p. 21-8 (2012).
[cited by applicant]
Kalinski et al., T-cell Priming by Type-I and Type-2 Polarized Dendritic Cells: The Concept of a Third Signal. Immunol Today, vol. 20, 561-7 (1999).
[cited by applicant]
Kalinski, P. & Okada, H. Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Seminars in immunology 22, 173-82 (2010).
[cited by applicant]
Kang et al., “HMGB1 in Cancer: Good, Bad, or Both?”, Clinical Cancer Research, vol. 19, No. 15, May 30, 2013, pp. 4046-4057.
[cited by applicant]
Karlin et al., Applications and Statistics for Multiple High-scoring Segments in Molecular Sequences, Proc. Natl. Acad. Sci. USA, vol. 90, p. 5873-5877 (1993).
[cited by applicant]
Kaufman et al., Oncolytic viruses: a new class of immunotherapy drugs, Nature Reviews, Drug Discovery, 2015, vol. 14(9), p. 642-62.
[cited by applicant]
Kelly et al., Real-time Intraoperative Detection of Melanoma Lymph Node Metastases using Recombinant Vaccinia Virus GL V-1 h68 in an Immunocompetent Animal Model. International Journal of Cancer. vol. 124, p. 911-8 (200…
[cited by applicant]
Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994.
[cited by applicant]
Khuri et al., A Controlled Trial of Onyx-015, an EIB Gene-deleted Adenovirus, in Combination with Chemotherapy in Patients with Recurrent Head and Neck Cancer. Nature Medicine, vol. 6, p. 879-885 (2000).
[cited by applicant]
Kim et al., Antibody Association with HER-2/neu-targeted Vaccine Enhances CD8 T Cell Responses in Mice Through Fe-mediated Activation of DCs. The Journal of Clinical Investigation, vol. 118, p. 1700-11 (2008).
[cited by applicant]
Kim et al., Oncolytic and Immunotherapeutic Vaccinia Induces Antibody-mediated Complement-dependent Cancer Cell Lysis in Humans. Science Translational Medicine, vol. 5, 185ra63 (2013).
[cited by applicant]
Kim et al., Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF. Mol Ther, vol. 14, p. 361-70 (2006).
[cited by applicant]
Kirn et al., Enhancing Poxvirus Oncolytic Effects through Increased Spread and Immune Evasion. Cancer Res, vol. 68, p. 2071-5 (2008).
[cited by applicant]
Kirn et al., Replication-selective Virotherapy for Cancer: Biological Principles, Risk Management and Future Directions. Nat Med, vol. 7, p. 781-7 (2001).
[cited by applicant]
Kirn et al., Targeted and Armed Oncolytic Poxviruses: A Novel Multi-mechanistic Therapeutic Class for Cancer. Nat Rev Cancer, vol. 9, p. 64-71 (2009).
[cited by applicant]
Kirn et at., Targeting of Interferon-beta to Produce a Specific, Multi-mechanistic Oncolytic Vaccinia Virus. PLoS Med, vol. 4, e353 (2007).
[cited by applicant]
Asagoe, et al; Down-Regulation of CXCR2 Expression on Human Polymorphonuclear Leukocytes by TN F-a1. J Immunol, 1998, vol. 160, No. 9, p. 4518-4525.
[cited by applicant]
Billottet et al., CXCR3, a double-edged sword in tumor progression and angiogenesis, Biochimica et Biophysica Acta, 2013, vol. 1836, p. 287-295.
[cited by applicant]
Cronin et al., Bacterial-Mediated Knockdown of Tumor Resistance to an Oncolytic Virus Enhances Therapy, Mol Ther, 2014, vol. 22, No. 6, p. 1188-1197.
[cited by applicant]
Dey et al., Intranasal Oncolytic Virotherapy with CXCR4-Enhanced Stem Cells Extends Survival in Mouse Model of Glioma, Stem Cell Reports, 2016, vol. 7, p. 471-482.
[cited by applicant]
Malvoisin E, et al, Soluble chemokine receptor CXCR4 is present in human sera. Anal Biochem., 2011, vol. 414, No. 2, p. 202-7.
[cited by applicant]
Manthey et al., “Complement component 5a (C5a)”. The International Journal of Biochemistry & Cell Biology, 2009, vol. 41, No. 11, p. 2114-2117.
[cited by applicant]
Pettit et al., Vaccinia Virus Transfection of Hippocampal Slice Neurons, Neuron, 1995, vol. 14, p. 685-688.
[cited by applicant]
Rein, D.T., et al., Evaluation of tissue-specific promoters in carcinomas of the cervix uteri. J. Gene Med., 2004, vol. 6, p. 1281-1289.
[cited by applicant]
Schonbeck U, “The CD40/CD154 receptor/ligand dyad”. Cellular and Molecular Life Sciences. 2001, vol. 58, No. 1, p. 4-43.
[cited by applicant]
Zhang JM, An J. Cytokines, inflammation, and pain. Int Anesthesiol Clin., 2007, vol. 45, No. 2, p. 27-37.
[cited by applicant]
Zhou et al., Tumor-targeting bacteria engineered to fight cancer, Nat Rev Cancer, 2018, vol. 18, p. 727-743.
[cited by applicant]
Konetschny et al., Generation of Transduction-Competent Retroviral Vectors by Infection with a Single Hybrid Vaccinia Virus, Journal of Virology, 2003, vol. 77, No. 12, p. 7017-7025.
[cited by applicant]
Paolino et al., Drug delivery systems, Encyclopedia of Medical Devices and Instrumentation, 2006, p. 437-495.
[cited by applicant]
Cohen et al., Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer, Breast Cancer: Basic and Clinical Research, 2017, vol. 11, p. 1-12.
[cited by applicant]
Deng et al., Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9. Oncotarget, 2017, vol. 8, No. 25, p. 40533-40543.
[cited by applicant]
Harte et al. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med. 2003, vol. 197, No. 3, p. 343-351.
[cited by applicant]
Muller et al., Engineering NK Cells Modified with an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Gliobastoma, J Immunother, 2015, vol. 38, No. 5, p.…
[cited by applicant]
Sanchez-Puig et al., Susceptibility of different leukocyte cell types to Vaccinnia virus infection, Virgology Journal, 2004, vol. 1, No. 10, p. 1-7.
[cited by applicant]
Schcheilkunov, Human Monkeypox and small pox viruses: genomic comparison, FEBS Letters, 2001, vol. 509, p. 66-70.
[cited by applicant]
Wallace et al., The role of chemokines and their receptors in ocular disease, Progress in Retinal and Eye Research, 2004, p. 435-448.
[cited by applicant]
Wendel et al., Natural Killer Cell Accumulation in Tumors is Dependent on IFNγ and CXCR3 Ligands, Cancer Res., 2008, vol. 68, No. 20, p. 8437-8445.
[cited by applicant]
Zhao et al., CXCR4 over-expression and survival in cancer: A system review and meta-analysis, Oncotarget, 2014, vol. 6, No. 7, p. 5022-5044.
[cited by applicant]
Zhang et al., Optimizing DC Vaccination by Combination with Oncolytic Adenovirus Coexpressiong IL-12 and GM-CSF, Molecular Therapy, Aug. 1, 2011, v19(8), p. 155-1568.
[cited by applicant]
Chen, et al., Cancers take Their Toll—The Function and Regulation of Toll-like Receptors in Cancer Cells. Oncogene, vol. 27, p. 225-33 (2008).
[cited by applicant]
Chen, et al., Regulating Cytokine Function Enhances Safety and Activity of Genetic Cancer Therapies. Molecular Therapy : The Journal of the American Society of Gene Therapy, vol. 21, p. 167-74 (2013).
[cited by applicant]
Cheng et al., Anticancer Function of Polyinosinic-Polycytidylic Acid. Cancer Biology & Therapy, vol. 10, p. 1219-23 (2011).
[cited by applicant]
Chertova et al. “Characterization and Favorable in Vivo Properties of Heterodimeric Soluble IL-15/IL-15Rα Cytokine Compared to IL-15 Monomer,” Journal of Biological Chemistry, May 6, 2013, vol. 288, pp. 18093-18103.
[cited by applicant]
Cho, et al., Isolation and Molecular Characterization of Cancer Stem Cells in MMTV-Wnt-1 Murine Breast Tumors. Stem Cells, vol. 26, p. 364-71, 2008.
[cited by applicant]
Choi et al., From benchtop to bedside: a review of oncolytic virotherapy, Biomedicines, 2016, vol. 4(3), p. 1-20.
[cited by applicant]
Coffin, R. Clinical Updates with oncolytic HSV. in 7th International Oncolytic Virus Meeting (Quebec City, 2013).
[cited by applicant]
Colamonici et al., Vaccinia Virus B18R Gene Encodes a Type 1 Interferon-Binding Protein that Blocks Interferon a Transmembrane Signaling, J. Biol. Chem. vol. 270(27):, p. 5974-8. 1005, 1995.
[cited by applicant]
Corpet et al., Multiple Sequence Alignment with Hierarchical Clustering, Nucleic Acids Research, vol. 16, p. 10881-10890, 1988.
[cited by applicant]
Couedel et al., Diverse CD1d-Restricted Reactivity Patterns of Human T Cells Bearing “invariant” AV24BV11 TCR, Eur. J. Immunol., vol. 28, p. 4391-4397, 1988.
[cited by applicant]
Dankort et al., BRafV600E cooperates with Pten silencing to elicit metastatic melanoma, Nat. Genet. 2009; vol. 41, No. 5, pp. 544-552.
[cited by applicant]
Davies et al., The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms, J. Virol., vol. 67(3), p. 1688-92, 1993.
[cited by applicant]
Dehoon et al., Open source clustering software, Bioinformatics 2004, vol. 20(9), pp. 1453-1454.
[cited by applicant]
Delgoffe et al., Enhanced interaction between Hsp90 and raptor regulates mTOR signaling upon T cell activation, Mol. Immunol. 2009; vol. 46(13), p. 2694-8.
[cited by applicant]
Di Pilato M, et al., Distinct Roles of Vaccinia Virus NF-κB Inhibitor Proteins A52, B15, and K7 in the Immune Response, J Virology, vol. 91, Issue 13, e00575-17, 2017.
[cited by applicant]
Doe et al., Induction of HIV-1 envelope (gp120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans, Eur. J. Immunol., (1994), vol…
[cited by applicant]
Donnenberg, et al., Rare-Event Analysis of Circulating Human Dendritic Cell Subsets and Their Presumptive Mouse Counterparts, Transplantation, vol. 72, p. 1946-1951, 2001.
[cited by applicant]
Dowty and Wolff, ed, Gene Therapeutics, Methods and Applications of Direct Gene Transfer, Birkhauser, Boston, USA (1994).
[cited by applicant]
Drugs and Pharmaceutical Sciences, Pharmaceutical Preformulation and Formulation, 2nd Edition, Gibson Ed., CRC Press LLC: Boca Raton, FL, 2004.
[cited by applicant]
Durham et al. “Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy,” Molecular Therapy, Aug. 30, 2017 (Aug. 30, 2017), vol. 25, No. 8, pp. 1917-1932.
[cited by applicant]
Earl et al., Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities, J of Virology, vol. 68, No. 5, 1994.
[cited by applicant]
Earl et al., Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus, J. Virol., vo…
[cited by applicant]
Ehrlich, et al., Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells, J. Immunol., vol. 174, p. 1922-1931, 2005.
[cited by applicant]
Eisenberg, et al, Real-time Intraoperative Detection of Breast Cancer Axillary Lymph Node Metastases using a Green Fluorescent Protein-expressing Herpes Virus. Annals of surgery, vol. 243, p. 824-30; discussion 830-2 (2…
[cited by applicant]
Elbashir, S. M. et al., RNA Interference is Mediated by 21- and 22-Nucleotide RNAs, Genes & Development, vol. 15; p. 188-200, 2001.
[cited by applicant]
Emoto, et al., Transient Control of Interleukin-4-Producing Natural Killer T Cells in Liver of Listeria Monocytogenes-Infected Mice by Interleukin 12, Infection Immunity, vol. 65, p. 5003-5009, 1997.
[cited by applicant]
Enzler, et al., Deficiencies of GM-CSF and Interferon Gamma Link Inflammation and Cancer. The Journal of Experimental Medicine, vol. 197, p. 1213-9 (2003).
[cited by applicant]
Ercolini et al., Recruitment of Latent Pools of High-avidity CDS(+) T Cells to the Antitumor Immune Response. The Journal of Experimental Medicine, vol. 201, p. 1591-602 (2005).
[cited by applicant]
Erickson et al., Hepatitis C Virus-Specific CTL Responses in the Liver of Chimpanzees with Acute and Chronic Hepatitis C, J. Immunol., vol. 151. p. 4189-4199, 1993.
[cited by applicant]
Errington, F., et al., Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Therapy, vol. 13, p. 138-49 (2006).
[cited by applicant]
Evans et al., Enhancement of Antigen-Specific Immunity via the TLR4 Ligands MPL Adjuvant and Ribi.529, Summary of Clinical Trials, Expert Review Vaccines, vol. 2, No. 2, 2003.
[cited by applicant]
Fahy et al., Vaccinia Virus Protein C16 Acts Intracellularly to Modulate the Host Response and Promote Virulence, J. Gen. Virol., vol. 89, p. 2377-2387, 2008.
[cited by applicant]
Falivene et al., Improving the MVA vaccine Potential by Deleting the Viral Gene Coding for the IL-18 Binding Protein. PLoS One 7, e32220, 2012.
[cited by applicant]
Falkner et al., Transient Dominant Selection of Recombinant Vaccinia Viruses, J Virol., vol. 64(6), p. 3108-3111, 1990.
[cited by applicant]
Farrell et al., Cloning, nucleotide sequence determination and expression of the
[cited by applicant]
Feoktistova, et al., clAPs Block Ripoptosome Formation, a RIPI/caspase-8 Containing Intracellular Cell Death Complex Differentially Regulated by cFLIP Isoforrns. Molecular Cell, vol. 43, p. 449-63 (2011).
[cited by applicant]
Feuerer et al., Fat Treg Cells: a Liaison Between the Immune and Metabolic Systems, Nat Med, vol. 15(8), p. 930-9, 2009.
[cited by applicant]
Filipazzi et al., Identification of a New Subset of Myeloid Suppressor Cells . . . Antitumor Vaccine. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 25, p. 2546-53 (20…
[cited by applicant]
Fountzilas et al., Review: Oncolytic Virotherapy, Updates and Future Directions, Oncotarget, vol. 8, p. 102617-39, 2017.
[cited by applicant]
Friedman et al., Hypoxia Moderates γ134.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures, Transl Oncol 2012, vol. 5(3), p. 200-7.
[cited by applicant]
Fujita, et al.COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells. Cancer Research, vol. 71, p. 2664-74, 2011.
[cited by applicant]
Fukata et al., Role of Toll-like Receptors in Gastrointestinal Malignancies. Oncogene, vol. 27, p. 234-43 (2008).
[cited by applicant]
Furtek et al., Strategies and Approaches of Targeting STAT3 for Cancer Treatment, ACS Chem. Biol., vol. 11(2), p. 308-318 (2016).
[cited by applicant]
Galon J. et al., Type, Density, and Location of Immune Cells within Human Colorectal Tumors Predict Clinical Outcome. Science, vol. 313, p. 1960-4 (2006).
[cited by applicant]
Garber, K., China Approves World's First Oncolytic Virus Therapy for Cancer Treatment. J Natl Cancer Inst, vol. 98, p. 298-300 (2006).
[cited by applicant]
Gaston et al., Production of Bioactive Soluble Interleukin-15 in Complex with Interleukin-15 Receptor Alpha from a Conditionally-Replicating Oncolytic HSV-1, PLOS One, 2013, vol. 8, No. 11, p. e81768.
[cited by applicant]
Gil et al., Targeting CXCL 12/CXCR4 Signaling with Oncolytic Virotherapy Disrupts Tumor, Vasculature and Inhibits Breast Cancer Metastases, Proceedings of the National Academy of Sciences, Mar. 13, 2013, vol. 110, No. 1…
[cited by applicant]
Ginestier, et al. CXCR1 Blockade Selectively Targets Human Breast Cancer Stem Cells in Vitro and in Xenografts. The Journal of Clinical Investigation, vol. 120, p. 485-97 (2010).
[cited by applicant]
Gmachl et al., The human sperm protein PH-20 has hyaluronidase activity; FEBS Letters, 1993, vol. 336, No. 3, p. 545-548.
[cited by applicant]
Gnant et al., Tumor-specific Gene Delivery using Recombinant Vaccinia Virus in a Rabbit Model of Liver Metastases. J Natl Cancer Inst, vol. 91, p. 1744-50 (1999).
[cited by applicant]
Aitken et al, “Brief Communication; A Heterologous Oncolytic Bacteria-Virus Prime-Boost Approach for Anticancer Vaccination in Mice”, J Immunother, vol. 41, p. 125-129, 2018.
[cited by applicant]
Borkotoky et al., The highly efficient T7 RNA polymerase: A wonder macromolecule in biological realm, Int. Journ of Biological Macromolecules, 2018, vol. 118, p. 49-50.
[cited by applicant]
Chan et al., Oncolytic Pxviruses, Annu Rev Viro, 2014, vol. 1, p. 191-214.
[cited by applicant]
Chen et al., Oncolytic Viruses, Advances in Virology, vol. 2012, Article 320206, 2 pages.
[cited by applicant]
Czajkowsky et al., Fe-fusion proteins: new developments and future perspectives. EMBO Mol Med. 2012, vol. 4, p. 1015-1028.
[cited by applicant]
Davanloo et al., Cloning and expression of the gene for bacteriophage T7 RNA polymerase, Proc Natl Acad Sci USA, Apr. 1984, vol. 81, p. 2035-2039.
[cited by applicant]
Guo et al., Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res. 2013, v3(1), p. 1-20.
[cited by applicant]
Hoffman, Tumor-seeking
[cited by applicant]